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As the number of studies examining the relationship betweenplasma concentrations of antituberculosis (anti-TB) drugs
and treatment response is limited, our Indonesian-Dutch team
performed a practical field pharmacokinetic study recently pub-
lished in this journal (1). Despite large interindividual variability
in plasma concentrations of TB drugs at 2 h postdose (C2 h), no
associations were found between isoniazid, rifampin, and pyrazi-
namide C2 h values and sputum culture results after 8 weeks of TB
treatment. These results contrast with findings in several (2–6) but
not all (7, 8) similar studies.
Akkerman et al. reiterate several limitations and consider-
ations that were already mentioned by us in our publication, in-
cluding that only a single sample at 2 h postdose was taken to
estimate maximum concentrations in serum (Cmax) of the TB
drugs; assessment of total exposure (the area under the concen-
tration-time curve from 0 to 24 h [AUC0-24 h]) would be prefera-
ble.However, sampling at 2 hwas not performed to estimateCmax,
but rather C2 h values were used as a correlate of total exposure
(AUC
0-24 h
) or Cmax. Very high correlations were found between
rifampin’s C2 h and AUC0-24 h (Spearman’s , 0.950; P  0.001)
and between isoniazid’s C2 h and AUC0-24 h (Spearman’s , 0.967;
P 0.001), yet the correlationwas less for pyrazinamide’s C2 h and
AUC0-24 h values (Spearman’s , 0.700; P 0.04), asmentioned in
our paper (1). Thus, sampling at 2 h postdose was actually meant
as a “limited-sampling strategy.” Nevertheless, we agree that a
single sample is often suboptimal for estimating AUC0-24 h, and
any limited-sampling approach should be evaluated in terms of
predictive performance (bias, precision) if enough full pharmaco-
kinetic curves are available. Recently, we developed limited-sam-
pling equations for simultaneous assessment of AUC0-24 h values
of all first-line TB drugs in Dutch patients, and similar equations
may be derived for Indonesian TB patients (9).
In this respect, we also emphasize that we did not perform
“classical C2 h monitoring” in the sense that we used predeter-
mined Cmax cutoff values to classify patients as having either low
or adequate drug concentrations based on their C2 h values. In-
stead, odds ratios (ORs) for a poor treatment response were as-
sessed for an interquartile range increase inC2 h, i.e., an increase in
C2 h values from the 25th percentile to the 75th percentile of the
observed C2 h values (interquartile OR).
Akkerman et al. also point to MIC values, which were not as-
sessed in our study to calculate pharmacodynamic indices of the
TB drugs. Of course,MIC values should ideally bemeasuredwhen
exposure-response relationships are evaluated. Our practical field
study allowed only for an assessment of drug susceptibility, and
patients with drug-resistant isolates were excluded. Available
studies that found associations between exposure and response for
TB drugs did so without taking MIC values into consideration
(2–6).
Akkerman et al. question howmuch closer we are to predicting
response based on plasma concentrations of anti-TB drugs after
our study. Despite its limitations, we still believe that our study of
a relatively large cohort of 181 patients suggests that such a pre-
diction is not easily possible in Indonesian pulmonary TB pa-
tients, based on C2 h values of isoniazid, rifampin, and pyrazin-
amide that correlate with AUC0-24 h values.We are puzzled by this
finding, enumerated several possible explanations in our paper,
and have started follow-up research into the pharmacokinetics
and pharmacodynamics of TB drugs in Indonesian TB patients.
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